ARNI in HFrEF—One-Centre Experience in the Era before the 2021 ESC HF Recommendations

Background: Sacubitril/valsartan, an angiotensin receptor–neprilysin inhibitor (ARNI), has demonstrated a survival benefit and reduces heart failure hospitalization in patients with heart failure with reduced left ventricular ejection fraction (HFrEF); however, our experience in this field is limite...

Descripción completa

Detalles Bibliográficos
Autores principales: Niemiec, Rafał, Morawska, Irmina, Stec, Maria, Kuczmik, Wiktoria, Swinarew, Andrzej S., Stanula, Arkadiusz, Mizia-Stec, Katarzyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8872461/
https://www.ncbi.nlm.nih.gov/pubmed/35206278
http://dx.doi.org/10.3390/ijerph19042089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8872461/
https://www.ncbi.nlm.nih.gov/pubmed/35206278
http://dx.doi.org/10.3390/ijerph19042089

Ejemplares similares